跳至主要内容
临床试验/NCT02681926
NCT02681926已完成不适用

VISITALY-Impact of a New Ablation Tracking Tool in Paroxysmal Atrial Fibrillation Ablation With Contact Force Technology

Giulio Zucchelli1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2015年12月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
200
试验地点
1
主要终点
Freedom from atrial fibrillation or other sustained atrial arrhythmias during 12 month after ablation, excluding 3 month of blanking period.

研究概览

简要总结

Pulmonary vein isolation (PVI) is the cornerstone of atrial fibrillation (AF) ablation. A novel technology was recently developed to allow an automatic points annotation when indirect parameters of lesion formation reach predefined target values.

The aim of the study was to evaluate, in a prospective and multicenter study, the safety, efficiency and PVI effectiveness of a new ablation tracking tool (VISITAG; Biosense Webster) during paroxysmal AF ablation using a contact force sensing catheter.

详细描述

Background:

Catheter ablation is an effective treatment for paroxysmal atrial fibrillation (PAF) and pulmonary vein isolation is the most prevalent approach for catheter ablation of this kind of arrhythmia. Long-term success of the procedure is diminished by arrhythmia recurrences occurring predominantly because of reconnections in previously isolated pulmonary veins. The durability of pulmonary vein isolation is the cornerstone of the ablation and is influenced by transmurality and continuity of lesions. Limited animal and human studies suggest a correlation between electrode-tissue contact and radiofrequency lesion generation. Particularly, some contact forces (CFs) parameter (minimum contact force and minimum force time integral values) were strong predictors of gap formation in small studies . High contact force during ablation was also associated with the incidence of steam pop and with the subsequent risk of cardiac tamponade. A recent multicenter trial demonstrated that the irrigated CF-sensing catheter is safe and effective for the treatment of drug refractory symptomatic PAF, with no unanticipated device-related adverse events. The increased percent of time within investigator-targeted CF ranges correlated with increased freedom from arrhythmia recurrence. Stable CF during radiofrequency application increased the likelihood of 12-month success. Real-time measurement of contact force (CF) during catheter ablation of PAF has been recently confirmed to potentially impact procedural outcome, while in another small study, whatever CF visualization could assist operators in avoiding both low and high CF, CF-guided ablation did not affect AF recurrence. A recent tool, called VISITAG, has been developed (and approved by EMEA) for Biosense Webster Navistar Smart Touch catheter in order to allow collection of ablation points with pre-determined characteristics, such as stability of catheter during ablation, mean contact force, drop in impedance. The aim of this tool is to improve success rate of the procedure, reducing site of reconnections with a better understanding of lesion formation point by point, and in parallel to reduce complications, avoiding to give unnecessary ablation shots in sites already treated with a good set of lesions.

Purpose:

The aim of the study was to evaluate the effectiveness and safety of a strategy using a new ablation tracking tool (VISITAG; Biosense Webster) during PAF ablation with contact force technology.

Design:

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • PAF undergoing first ablation
  • Patient was above the minimum age as required by local regulations to be participating in a registry regardless of gender and race;
  • Provided Signed Informed Consent for the procedure.

排除标准

  • Patient had not to be included if any of the following conditions existed:
  • Persistent or permanent atrial fibrillation;
  • Redo ablation
  • Left atrium diameter (LAD) > 50 mm
  • Participation in another drug or device study that would have jeopardized the appropriate analysis of end-points of this study.
  • High probability of non-adherence to the follow-up requirements (due to social, psychological or medical reasons)
  • Pregnancy

结局指标

主要结局

Freedom from atrial fibrillation or other sustained atrial arrhythmias during 12 month after ablation, excluding 3 month of blanking period.

时间窗: up to 12 months after ablation

To determine the effectiveness at 12 month of a new ablation tracking tool called VISITAG (Biosense Webster) .

Freedom from major and minor complications during 1 month after ablation (SAFETY OUTCOME)

时间窗: up to 1 month after ablation

To determine the safety at 1 month of a new ablation tracking tool called VISITAG (Biosense Webster)

次要结局

  • Comparison of incidence of complications during 1 month after ablation using different VISITAG settings.(up to 1 month after ablation)
  • Freedom from atrial arrhythmias during 12 months after ablation (excluding 3 month blanking period) using different VISITAG settings.(up to12 months after ablation)
  • Radiofrequency duration and procedural duration using different VISITAG settings.(procedure)

研究者

申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Giulio Zucchelli

MD, PhD

Azienda Ospedaliero, Universitaria Pisana

研究点 (1)

Loading locations...

相似试验